Company is focusing capital resources on three prioritized programs that reflect Omega’s unique value proposition to enable precision epigenomic control for potential therapeutic advantages versus ...
CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a biotechnology company pioneering the development of a new class of programmable epigenomic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback